A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2014

Conditions
CancerOncologyTumorsAdvanced MalignancyAdvanced Solid TumorsOncology Patients
Interventions
DRUG

AMG 208

AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.

Trial Locations (3)

63110

Research Site, St Louis

77030

Research Site, Houston

90211

Research Site, Beverly Hills

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY